Sai Life Sciences, Agility Life Sciences, and Centrix Pharma team up to accelerate drug development for innovators

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions has announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services.

The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing. 

Through this partnership, customers will have access to integrated drug substance and drug product development, helping them move efficiently from preclinical studies to first-in-human (FIH) clinical trials and beyond.  

By combining deep expertise across the CMC value chain, the Integrated CMC Partnership helps customers create and execute holistic development plans—translating molecular hits into new medicines. Key benefits include: 

• Broad scientific expertise across multiple disciplines, supported by extensive laboratory and manufacturing facilities 
• End-to-end service coverage from synthetic route scouting to drug substance manufacturing, and from pre-formulation through to clinical trial material manufacturing
• Cross-functional optimization: integrated planning across API and drug product development, reducing duplication, risks, costs, and timelines 
• Agility and flexibility to respond proactively to emerging technical risks across functions
• Seamless coordination between technical teams, including proactive sample transfer and early API evaluation in the drug product process 
• Single point of contact from Day One, ensuring alignment and accountability throughout project execution